Navigation Links
European Centre for Modern Drug Discovery Established in Hamburg
Date:9/3/2007

HAMBURG, Germany, September 3 /PRNewswire-FirstCall/ -- Hamburg is on its way to becoming a leading hub of Europe's academic drug discovery, with the northern German city's town hall today announcing the foundation of European ScreeningPort GmbH, a company that will run a state-of-the-art drug discovery service centre. European ScreeningPort is being established with the support of the German Federal Ministry of Education and Research, the Free and Hanseatic City of Hamburg, Evotec AG and Norgenta, the north German life science agency. Although still in an early phase, the project has already raised more than EUR 7 million in financing.

Hamburg's new European ScreeningPort will build upon research results generated in academia. It will enable a more systematic and efficient search for promising new compounds which can subsequently be further developed. Both Evotec AG and the City of Hamburg have invested into the newly founded company, which will be run as a public private partnership. This novel concept in advancing drug discovery will also be supported with considerable funds from the German Federal Ministry of Education and Research.

ScreeningPort provides the missing link in Europe between academic research and the pharmaceutical industry. The research centre will accelerate translating promising results generated in basic research on the causes of diseases into new therapeutics. ScreeningPort will act as a service provider that enables academic research institutes to access its state-of-the-art technology, its vast amount of chemical compounds as well as its sample and data processing capabilities. New therapeutic concepts developed at universities can, in future, undergo the same standardised, more efficient and thus more cost-effective development processes that have, until now, been available only to industry. Pharmaceutical and biotech companies, for their part, can benefit from the research results generated at ScreeningPort and thus complement their own drug research.

ScreeningPort is planned to be at the heart of an international network. Although it is still at an early stage, a number of European research institutes have already been tied in. Among others, the Swiss Federal Institute of Technology (ETH Zurich) and the Vienna-based Institute of Molecular Biotechnology of the Austrian Academy of Sciences have signed letters of intent.

The ScreeningPort project was initiated by Evotec AG, a leading drug discovery and development company, bringing in its extensive expertise. It was implemented by Norgenta GmbH, the north German life science agency that promotes the structural development of life sciences in the federal states of Hamburg and Schleswig-Holstein.

Other partners are also raring to go, such as c.a.r.u.s. IT AG, a company specialised in high-performance data management solutions for life sciences.

Statements:

Thomas Rachel, member of the German federal parliament and parliamentary secretary of state at the German Federal Ministry of Education and Research:

"ScreeningPort is an important element to close the gap between basic research and the commercial development of new therapeutics. Therefore the Federal Ministry of Education and Research has decided to financially support, as part of its Pharmaceuticals Initiative for Germany campaign, the establishment of the ScreeningPort and initial pilot projects in screening. Total funding of more than EUR 800 million will be provided by 2011 under this initiative which is aimed at accelerating the development of innovative therapeutics for patients."

Senator Gunnar Uldall, Head of the State Ministry of Economic and Labour Affairs, City of Hamburg:

"By funding and implementing this project, we continue and further complement our successful cluster policy for the life sciences in northern Germany. The new ScreeningPort provides Hamburg with the opportunity to become a leading European centre of modern pharmaceutical research."

Senator Jorg Drager, Head of the State Ministry of Science and Research, City of Hamburg:

"Establishing the European ScreeningPort in Hamburg is an important milestone in the development of the life science cluster in northern Germany. Together with our partners, the Federal Ministry of Education and Research and Evotec AG, we are building a state-of-the-art research infrastructure from which universities in Germany and beyond will be able to benefit. Having this infrastructure for scientist to develop drug candidates for innovative therapeutics in place is a huge success for our scientific region and proof of the good work conducted by Norgenta, the cluster agency of Hamburg and Schleswig-Holstein."

Jorn Aldag, President & Chief Executive Officer of Evotec AG:

"We know from our many years of experience as a leading European partner in drug discovery for pharmaceutical and biotech companies worldwide, and from our own research on diseases of the Central Nervous System that academic research generates a plethora of excellent scientific ideas that require an industrial environment for further development. The initial step in this development is the search to identify biologically active chemical compounds. The European ScreeningPort provides us with the link that translates scientific discoveries into results that pharmaceutical and biotechnological companies, such as Evotec, can build upon."

Dr Kathrin Adlkofer, Managing Director of the North German Life Science Agency Norgenta:

"Our main objective is to bring together existing excellence in science and business. ScreeningPort will see a unique network of partners in academia and industry who will mutually be able to benefit from pooling their expertise in medical science, technological know-how and industrial performance."

Contact:

Press office of the German Federal Ministry of Education and Research

Katrin Hagedorn

P +49-30-1857-5051

katrin.hagedorn@bmbf.bund.de

Evotec AG

Anne Hennecke

P +49-40-56-081-286

anne.hennecke@evotec.com

Norgenta GmbH

Ina Akkerman

P +49-40-471-96-418

ina.akkerman@norgenta.de

Press office of the State Ministry of Economic and Labour Affairs, Free

and Hanseatic City of Hamburg

Arne Maydell

P +49-40-428-41-3015

arne.maydell@bwa.hamburg.de

Press office of the State Ministry of Science and Research, Free and

Hanseatic City of Hamburg

Janis Eitner

P +49-40-428-63-23-22

pressestelle@bwf.hamburg.de

c.a.r.u.s. IT AG

Matthias Rath

P +49-40-51435-2410

contact.presse@carus-it.com


'/>"/>
SOURCE Evotec AG
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Mirus granted European patent for gene therapy
2. Info security group announces first Eastern European chapter
3. EMD Biosciences partners with European biotech company
4. Third Wave lands European distribution deal, reports high earnings
5. The combination of monolithic columns and modern HPLC/MS/MS instrumentation for high chromatographic throughput and sensitive detection of beta-agonists
6. A (modern) Tale of Two Cities: Milwaukee and Madison inch together
7. Building the modern public-purpose university should be UW Systems goal
8. Modernizing the tax code can make Wisconsin tech businesses more competitive
9. SEESNP DISCOVERY
10. siRNA screening of the cell cycle with two dynamic GFP sensors (from Discovery Matters Issue 1, July 2005)
11. Exploiting the Life Science Data Explosion to Speed New Drug Discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... March 23, 2017  SeraCare Life Sciences, ... in vitro diagnostics manufacturers and clinical laboratories, ... first multiplexed Inherited Cancer reference material ... by next-generation sequencing (NGS). The Seraseq™ Inherited Cancer ... input from industry experts to validate the ...
(Date:3/23/2017)... ... March 23, 2017 , ... Ellen ... the Connecticut Technology Council (CTC) as a 2017 Women of Innovation® finalist. Matloff ... of Innovation Awards Dinner. , The dinner recognizes women accomplished in science, technology, ...
(Date:3/23/2017)... 2017 According to a report by Transparency ... fragmented due to the presence of a large pool of participants; ... Fisher , and Sigma-Aldrich, compete with each other in this market. ... more than 76% of this market in 2016.  ... As of now, a large number ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... monitoring solutions, today announced the hire of Dr. Sigmund “Sig” Floyd as Vice ... applications, strategic partnerships and joint development activities. , “Dr. Floyd’s career has spanned ...
Breaking Biology Technology:
(Date:2/27/2017)... 27, 2017   Strategic Cyber Ventures , the ... led a $3.5 million investment in  Polarity , the ... Ventures is DC based and is led by cybersecurity ... . Ron Gula , also a longtime cybersecurity ... in this series A round of funding. This new ...
(Date:2/21/2017)... , February 21, 2017 ... 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr als ... einige Hindernisse zu überwinden gilt, um diese Prognose zu ... ... anderem die Mobilisierung der finanziellen Mittel für die Biobank, ...
(Date:2/10/2017)... , Feb 10, 2017 Research ... report "Personalized Medicine - Scientific and Commercial Aspects" ... ... medicine. Diagnosis is integrated with therapy for selection of treatment ... early detection and prevention of disease in modern medicine. Biochip/microarray ...
Breaking Biology News(10 mins):